Wolverine Order

The record · sourced

Every BPC-157 and TB-500 Claim, Traced to Its Source

The full reference list behind this site — the constituent studies, the recent reviews, and the FDA compounding pages that govern access. Each entry links to the primary source.

Read the researchWhere access stands

How to read this list

This is the complete reference set for the BPC-157 TB-500 material on this site. Findings tagged to BPC-157 draw on entries [1] through [5] and the recent reviews [9] through [11]; findings tagged to TB-500 draw on the Thymosin Beta-4 structural and review literature [6] through [8]. The regulatory section draws on the FDA compounding pages [12] through [14] and the access-pathway framework [21], which are the only sources used for any regulatory or access fact on this site.

A standing caveat applies to the TB-500 entries: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4, not the Ac-LKKTETQ heptapeptide actually sold under that name [8]. We have kept that distinction in the body copy throughout. Full citations, with DOIs and PubMed identifiers where available, are listed below.

  1. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  2. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. ↗
  3. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19:19066-19077. ↗
  4. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110:774-780. ↗
  5. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  6. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. ↗
  7. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. ↗
  8. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. ↗
  9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  11. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  12. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (list entries for BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; entries effective September 29, 2023). ↗
  13. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; 503A bulks-list framework). ↗
  14. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda lists BPC-157 and TB-500 among substances being considered for inclusion on the 503A Bulks List). ↗
  15. U.S. Food and Drug Administration. Human Drug Compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (lawful compounded-access pathway: licensed-prescriber evaluation, patient-specific prescription, 503A pharmacy or 503B outsourcing facility, with ingredient-eligibility requirements). ↗